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DNA constructs based on bacterial artificial chromosomes (BACs) are frequently used to generate transgenic animals as they
reduce the influence of position eﬀects and allow predictable expression patterns for genes whose regulatory sequences are not
fully identified. Despite these advantages BAC transgenics suﬀer from drawbacks such as complicated vector construction, low
eﬃciency of transgenesis, and some remaining expression variegation. The recent development of transcription activator-like
eﬀector nucleases (TALENs) and zinc finger nucleases (ZFNs) has resulted in new transgenic techniques which do not have the
drawbacks associated with BAC transgenesis. Initial reports indicate that such designer nucleases (DNs) allow the targeted insertion
of transgenes into endogenous loci by direct injection of the targeting vector and mRNA/DNA encoding the predesigned nucleases
into oocytes. This results in the transgene being inserted at a specific locus in themouse genome, thus circumventing the drawbacks
associated with BAC transgenesis.
Sophisticated transgenic mouse models frequently require
that the transgene expression is restricted to a particular
tissue or cell type as defined by a specific promoter. BACs
have been the most commonly used method for generation
of transgenic animals when the transcriptional control ele-
ments of the gene of interest have not been clearly identified.
Thus, in many applications BACs replaced “conventional”
transgenesis using short constructs with well-defined pro-
moter regions. BACs are based on the single-copy functional
fertility plasmid (F factor) of Escherichia coli. In contrast
to high copy number plasmids, replication of the F factor
is tightly controlled and the plasmid exists as only one or
two copies per cell. Unidirectional replication is determined
by the regulatory genes oriS and repE of the F plasmid
while the copy number is controlled by parA and parB
genes. These regulatory elements, together with a resistance
marker, constitute the BAC vector backbone that facilitates
cloning and stable propagation of DNA fragments up to
300 kilobase pairs [1]. Originally developed for construction
of genomic libraries used in the early genome sequencing
projects, BAC constructs and BAC libraries have also proven
to be very useful genetic tools in other aspects of basic
research.
As mentioned before, the use of BACs enabled scientists
to generate transgenes even when the promoter region of
a gene is unknown. Furthermore, BAC-based transgenes
more frequently yield the expected expression pattern among
founder lines compared to conventional transgenes. This is
most likely the result of reduced influence of position
eﬀects due to either the sheer size of the BAC transgenes
which insulate the transgene cassette from the influence of
the chromosomal environment or through the inclusion of
elements such as enhancers, silencers, locus control regions,
and matrix attachment regions. BAC transgenes can be
rapidly constructed through recombination in E. coli and
subsequently used to generate transgenic animals using
standard techniques such as pronuclear injection in case of
mice or rats (Figure 1(a)). This rapid and relatively straight
2 Journal of Biomedicine and Biotechnology
Transgene
cassette
BAC
Modified
BAC
Fertilized oocyte
GFP Kan(R)
Promoter 1 2 3 4
CM(R)
Recombination
Promoter GFP Kan(R) 1 2 3 4
Promoter GFP Kan(R) 1 2 3 4
Promoter GFP Kan(R) 1 2 3 4
CM(R)
Microinjection
Insert of BAC
Pronucleus
Random
integration
(a)
PCR amplification
NI
NN
HD
NGTALE monomer
templates
Linearized
hexamers
NN NI HD NI NN NG
H1-1 H1-2 H1-3 H1-4 H1-5 H1-6
NG NG HD NN NN NI
H2-1 H2-2 H2-3 H2-4 H2-5 H2-6
+
+
HD HD NG NN NI NI
H3-1 H3-2 H3-3 H3-4 H3-5 H3-6
+
TALEN cloning backbone
Golden gate digestion-ligation
0.5 repeat
(NI, HD, NN, or NG)
Fertilized oocyte
Targeting vector
mRNA
Microinjection
mRNA transcription
Customized
TALEN
N term ccdB cassette C term
N term C termNN NINI NI NI NINNNN NN NN HDHD HD HDNG NG NG NG
GFPHA HAIRES
X X
GFPHA HA
Pronucleus
FokI
IRES
GFPIRES
Target cleavage
Repair via homologous
recombination
Specific
integration
FokI domain
(b)
Figure 1: Genomic modifications through BACs and TALEN. (a) The recombination of the BAC and a transgene (GFP and the antibiotic
resistance gene kanamycin) leads to a modified BAC which is then randomly integrated into the DNA after microinjection into the male
pronucleus. (b) The customized TALEN, specific to the sequence of interest, is constructed by PCR and digestion-ligation of hexamers that
are cloned into the TALEN backbone. Subsequently, the TALEN is transcripted into RNA followed by the microinjection of the RNA into
the cytoplasm of the zygote simultaneous to the injection of the GFP containing targeting vector into the pronucleus. This results in specific
integration of the GFP via homologous recombination generating a knock-in locus.
forward approach ensured that BAC transgenesis remained a
viable alternative to the more complex and time-consuming
targeted transgene insertion via embryonic stem cell technol-
ogy [2].
Despite its increasing popularity the use of BAC transge-
nesis for the generation of transgenic animals is still accom-
panied by several problems. BAC transgenes are generated
by nonspecific integration into the target genome; therefore
a variable number of copies can be inserted into an unknown
locus in the genome of the target organism. Moreover,
because the generation of BAC transgenic founders is less
eﬃcient than conventional transgenes, it usually results in
less founder lines being generated in the course of a similar
microinjection eﬀort. Furthermore, the construction of a
BAC transgene can be extremely time consuming; while a
BAC transgene construct may be assembled within 2 weeks,
in some instances it takes several months. The construction
of the BAC is then followed, depending on the facility, by
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Figure 2: Generation of new mouse lines through BAC transgenesis or TALEN-mediated transgene insertion. (a) In consequence of the
random integration of the vector during the construction of BAC transgenic mice the founders need to be screened for the appropriate
expression pattern. (b) In contrast, TALEN-constructed transgenic mice only need to be checked by molecular biology methods for presence
of the appropriate knock-in event. As a side product, knock-out alleles are usually generated as well.
several months of oocyte injection and screening of the
founder lines (Figure 2(b)). New promising technologies
have been developed which may overcome the problems
associated with BAC transgenesis while retaining or even
improving on its advantages over conventional transgenesis.
These new techniques are based on designer nucleases and
their ability to generate double strand breaks (DSBs) at a
predetermined sequence in the target genome, even in the
oocyte. Such DSBs can be repaired by nonhomologous end-
joining (NHEJ) or homologous recombination (HR). While
NHEJ results in deletions or insertions that can lead to
gene deficiencies, HR can lead to the faithful integration
of a coinjected targeting vector. At the time of writing,
two classes of nucleases, ZFNs [3–5] and TALENs [6, 7],
show the most promise of making an impact on transgenic
technology in the mouse and beyond. Both assemble on the
target DNA as heterodimers and each feature a DNA-binding
domain designed for a specific sequence and a FokI domain
containing the endonuclease activity.
The DNA-binding domains of ZFNs are assembled
through multimerization of Cys2His2 motifs, each motif rec-
ognizing three nucleotides of the DNA. ZFNs are commonly
designed with 3- to 4-zincfinger domains [8], sometimes
even up to 6 fingers [9], which are then fused to the FokI
domain. The ZFNs dimerize at the target sequence and
cleave the double-stranded DNA thus forming DSBs. It is
thought that increasing the number of ZF domains leads
to an increase in the specificity and decreases the toxicity
of the ZFNs. Constructs containing ZFNs encoding for a
specific target can either be obtained from a commercial
source such as Sigma-Aldrich or constructed in-house.
The most common methods of in house construction are
through open-source protocols such as Oligomerized Pool
Engineering (OPEN) and Context-Dependent Assembly
(CoDA) arrays. OPEN utilizes an archive of zinc finger pools
specific to the sequence of interest. Multifinger arrays are
then generated from these pools and arrays which have
high aﬃnity and specificity are identified via a bacterial
two-hybrid system [10]. As with OPEN, CoDA is based on
a library and involves cloning the 3 fingers of the ZFNs
out of a large archive of 319 N terminal (F1) and 344 C
terminal (F3) fingers designed to work in combination with
18 fixed second fingers (F2) [11]. Compared to OPEN, this
method is easier and cheaper for laboratories to adopt as
no special techniques or proprietary reagents are required.
CoDA does however have some drawbacks; the identity
of the second finger is limited to the 18 fixed F2 units
and the combined aﬃnity or specificity of the 3 fingers in
combination is not taken into account. Therefore despite the
increased technical expertise required, at present OPEN may
still be the most reliable choice to achieve the high specificity
needed for certain therapeutic applications. Unfortunately
at present both OPEN and CoDA are restricted to 3 fingers
per heterodimer, thus limiting the possibility for increased
specificity through inclusion of additional fingers.
TALEN nucleases are similar to ZFNs as they rely on the
FokI domain for their nuclease activity. However, the DNA-
binding domain is based on the TAL-like eﬀectors originally
derived from Xanthomonas plant pathogens [12]. The TAL
DNA-binding domain consists of a number of repeats where
one repeat recognizes one base pair of the target DNA.
Each individual repeat is 33-35-amino-acids long and all
repeats are essentially identical with the exception of two
key amino acid in positions 12 and 13. It is these “repeat
variable diresidues” (RVDs) which determine the repeat’s
sequence specificity. In short, the RVDs NI, HD, NN, and
NG recognize A, C, G or A, and T, respectively. Since the
individual repeats appear to be modular and function in
a context-independent manner, it is possible to design a
TALEN protein that will bind and cleave virtually any target
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sequence. As with the ZFNs two TALEN monomers are
necessary to dimerize a FokI domain at the target sequence
for generating a DSB [7, 13]. Online tools are available to
custom-design TALEN targeted to a specific sequence. These
allow the rapid identification of a suitable target sequence
and its respective TALEN pair. Several strategies for eﬃcient
generation of TALEN pairs have been published including
strategies involving “Golden Gate cloning” that include the
assembling of repeat modules to an intermediary array with
up to 10 repeats followed by the ligation of intermediary
arrays into a backbone [7] or a PCR-based protocol where the
monomers of a plasmid library are amplified to first form 3
hexamers which are then ligated to one 18 mer. This protocol
enables the construction of customised TALEN within few
days [14] (Figure 1(b)). Several other TALEN construction
systems have been published [15–17] and TALENs can also
be obtained commercially.
The method of construction of TALENs and ZFNs may
be diﬀerent but the functional outcome of both methodolo-
gies is the same: they are eﬃcient and reliable methods for
the in vitro and in vivo production of gene deficiencies, gain
of function transgenics and perhaps most promisingly new
therapeutic applications. But how does this relate to BAC
transgenesis? In eﬀect, DN technology allows the insertion
of reporter genes such as GFP or Cre into the gene of
interest by mouse zygote injection. The ZFNs and TALENs
determine the exact position for integration of the transgene
via homologous recombination. To achieve this, transgene
vectors containing homologous sequences, flanking the DSB
as well as the transgene, are constructed and coinjected
with the DN expression vectors (or their mRNA) into the
zygotes. This results in integration similar to that achieved
by time-consuming embryonic stem (ES) cell culture, yet
obtained with the speed of conventional transgenesis and
without using selection genes such as neomycin resistance.
Moreover, the founder lines of transgenic animals generated
through BAC technology have to be functionally screened
thoroughly due to the expression variegation as result of the
randomness of the integration and an appropriate line has to
be identified. In the case of DN-assisted HR all founder lines
are carrying identical gene modifications and they can all
be used for functional confirmation and analysis (Figure 2).
While the eﬃciency of TALENs in mouse zygotes still needs
to be evaluated, ZFNs have already been shown to allow
eﬃcient integration of DNA into a target site such as the
frequently used gt(ROSA)26Sor locus [5, 18]. Thus, it may
be envisioned that in the future, BAC transgenes will not be
used to drive transgenesis but instead functional transgenes
will be directly integrated into endogenous loci. As with
insertion transgenes involving ES cell technology, this may
be achieved by either integration (or mutation) of the start
ATG, leading in most cases to a functional knockout allele,
or by placing the transgene in the 5′ untranslated region and
using an internal ribosomal entry site (IRES) or 2A element
thus maintaining the open reading frame of the “hijacked”
gene. Moreover placement of open reading frames under the
control of loxP-flanked STOP cassettes or even exogenous
promoters through placement of the respective constructs in
the target locations may also be envisaged. As a side product
these approaches would in many cases also yield deficiency
alleles after faulty NHEJ repair.
Though it may appear that the advent of DNs will make
BAC transgenesis all but obsolete, applications for BAC
transgenes remain. Detailed functional analysis of human
genetic elements in model organisms such as the mouse
is still likely to be carried out using BAC transgenesis.
Also, BACs may still serve as donors for homology regions.
Additionally, although this paper highlights some of the
future possibilities of genomic manipulation through DNs,
many obstacles both small and large still remain. These
include the determination of oﬀsite eﬀects (mutations) and
what outcomes they may have. Furthermore a gold standard
protocol for identification of target sequences and DNs must
still be validated in vivo and other considerations such as
the optimum length of homology regions for integration at
DSBs in oocytes, and whether the targeting vector should
be supplied in linear or circular form must still be decided.
Only then a full financial and scientific comparison of BAC
technology versus insertion through use of DNs will be
possible.
Taken together, this paper has discussed some of the
advantages and disadvantages of BAC technology in the
context of the newly evolving DN technology which allows
targeted insertions in the oocyte. We believe this is a
revolutionary time in transgenic technologies and that the
use of DN technology could make not only ES cell culture
techniques but also conventional transgenesis, including
BAC transgenesis all but obsolete.
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